Today Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) Reported Increase in Shorted Shares

March 17, 2018 - By Linda Rogers

 Today Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) Reported Increase in Shorted Shares

The stock of Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) registered an increase of 10.94% in short interest. ADMP’s total short interest was 2.91 million shares in March as published by FINRA. Its up 10.94% from 2.63M shares, reported previously. With 562,000 shares average volume, it will take short sellers 5 days to cover their ADMP’s short positions. The short interest to Adamis Pharmaceuticals Corporation’s float is 9.97%.

The stock increased 2.67% or $0.1 during the last trading session, reaching $3.85. About 878,185 shares traded or 9.55% up from the average. Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) has declined 52.09% since March 17, 2017 and is downtrending. It has underperformed by 68.79% the S&P500.

Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company has market cap of $128.54 million. The companyÂ’s specialty pharmaceutical product candidates comprise Epinephrine Injection pre-filled syringe for use in the emergency treatment of acute allergic reactions, including anaphylaxis; dry powder inhaler products consisting of albuterol (APC-2000) and fluticasone (APC-4000) for the treatment of bronchospasm and asthma; and beclomethasone (APC-1000), a metered dose inhaler product for the asthma, as well as APC-1000 and APC-5000 for the treatment of asthma and chronic obstructive pulmonary disease. It currently has negative earnings. It also operates a 503B drug outsourcing facility that provides prescription compounded medications to patients, physician clinics, hospitals, surgery centers, and other clients in the United States.

Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) Ratings Coverage

Among 4 analysts covering Adamis Pharma (NASDAQ:ADMP), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Adamis Pharma has $16 highest and $5 lowest target. $9.75’s average target is 153.25% above currents $3.85 stock price. Adamis Pharma had 9 analyst reports since December 1, 2015 according to SRatingsIntel. The stock has “Buy” rating by Maxim Group on Monday, June 12. Maxim Group maintained Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) rating on Thursday, July 21. Maxim Group has “Buy” rating and $10 target. The stock of Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) earned “Buy” rating by Maxim Group on Tuesday, December 1. The rating was maintained by Maxim Group with “Buy” on Monday, August 21. The stock has “Buy” rating by Raymond James on Tuesday, September 12. The firm has “Buy” rating given on Monday, December 4 by Raymond James.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.